38 patents
Utility
Coronavirus Vaccine Formulations
19 Oct 23
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines.
Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
Filed: 5 Dec 22
Utility
Modified RSV F Proteins and Methods of Their Use
21 Sep 23
The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and; or prevention of RSV infection.
Peter M. PUSHKO, Yingyun WU, Michael J. MASSARE, Ye LIU, Gale SMITH, Bin ZHOU
Filed: 10 Aug 22
Utility
Coronavirus Vaccine Formulations
9 Mar 23
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines.
Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
Filed: 27 Jan 21
Utility
Coronavirus vaccine formulations
3 Jan 23
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines.
Gale Smith, Michael J. Massare, Jing-Hui Tian
Filed: 8 Feb 21
Utility
Vaccine Compositions Having Improved Stability and Immunogenicity
8 Dec 22
Disclosed herein are nanoparticles suitable for use in vaccines.
Gale SMITH, Ye LIU, Jing-Hui TIAN, Michael J. MASSARE, Sarathi BODDAPATI, Erica SHANE, Cynthia OLIVER, Gregory GLENN
Filed: 23 May 22
Utility
Coronavirus and Influenza Compositions and Methods for Using Them
10 Nov 22
Disclosed herein are compositions and methods for inducing immune responses against both influenza and coronaviruses.
Nita PATEL, Bin ZHOU, Mimi GUEBRE-XABIER, Jing-Hui TIAN, Alyse D. PORTNOFF, Michael J. MASSARE, Vivek SHINDE, Louis FRIES, Gale SMITH
Filed: 4 May 22
Utility
Coronavirus Vaccine Formulations
20 Oct 22
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines.
Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
Filed: 22 Mar 22
Utility
Modified RSV F proteins and methods of their use
20 Sep 22
The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
Filed: 11 Oct 19
Utility
Quil a Fraction with Low Toxicity and Use Thereof
4 Aug 22
Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens.
Bror MOREIN, Karin LÖVGREN BENGTSSON, Jill EKSTRÖM, Katarina RANLUND, Kefei HU
Filed: 17 Sep 21
Utility
Vaccine compositions having improved stability and immunogenicity
21 Jun 22
Disclosed herein are nanoparticles suitable for use in vaccines.
Gale Smith, Ye Liu, Jing-Hui Tian, Michael J. Massare, Sarathi Boddapati, Erica Shane, Cynthia Oliver, Gregory Glenn
Filed: 21 Nov 17
Utility
Methods for Preventing Disease or Disorder Caused by RSV Infection
5 May 22
The present invention is generally related to modified or mutated respiratory syncytial virus (RSV) fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
Gregory GLENN
Filed: 25 Feb 20
Utility
Coronavirus Vaccine Formulations
28 Apr 22
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines.
Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
Filed: 10 Jan 22
Utility
Multivalent influenza nanoparticle vaccines
22 Mar 22
Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines.
Sarathi Boddapati, Anushree Herwadkar, Jason Wong, Yen-Huei Lin, Gale Smith, Jing-Hui Tian
Filed: 19 Mar 19
Utility
Multivalent Influenza Nanoparticle Vaccines
17 Mar 22
Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines.
Sarathi BODDAPATI, Anushree HERWADKAR, Jason WONG, Yen-Huei LIN, Gale SMITH, Jing-Hui TIAN
Filed: 24 Nov 21
Utility
Vaccine compositions having improved stability and immunogenicity
22 Feb 22
Disclosed herein are nanoparticles suitable for use in vaccines.
Gale Smith, Ye Liu, Jing-Hui Tian, Michael J. Massare, Sarathi Boddapati, Erica Shane, Cynthia Oliver, Gregory Glenn
Filed: 20 Aug 19
Utility
Coronavirus vaccine formulations
22 Feb 22
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines.
Gale Smith, Michael J. Massare, Jing-Hui Tian
Filed: 18 Mar 21
Utility
Methods and compositions for inducing immune responses against Clostridium difficile
21 Sep 21
Disclosed herein are methods and compositions for treating or preventing bacterial infection.
Jing-Hui Tian, Ye Liu, Gale Smith, Gregory Glenn, David Flyer
Filed: 15 Mar 18
Utility
Coronavirus Vaccine Formulations
29 Jul 21
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines.
Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
Filed: 8 Feb 21
Utility
Coronavirus Vaccine Formulations
29 Jul 21
Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines.
Gale SMITH, Michael J. MASSARE, Jing-Hui TIAN
Filed: 18 Mar 21
Utility
Modified RSV F proteins and methods of their use
6 Jul 21
The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
Filed: 15 Jun 18